Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Covington Advises Horizon Discovery Group plc on a Key Acquisition

June 5, 2014

LONDON, 5 June, 2014 —Horizon Discovery Group plc, an AIM listed international life science company supplying research tools and services to organizations engaged in genomics research and the development of personalized medicines, announced its acquisition of the CombinatoRx service business and related assets from Nasdaq listed Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain. Covington & Burling advised Horizon on the transaction.

The new business will become Horizon CombinatoRx Incorporated, a wholly owned subsidiary of Horizon. Horizon CombinatoRx, Inc. will be located in 23,000 sq. ft. of laboratory and office space in Kendall Square, Cambridge, MA, providing a base for future growth of Horizon’s business operations in North America.

The Covington team was led by partner Kristian Wiggert and associate Philip Young, with assistance from Morag Peberdy (intellectual property), Mike Francese (employee benefits), Heather Haberl (real estate) and Rob Heller (tax).

Share this article: